New results from a decade-long clinical trial point to gene therapy as a feasible treatment option for children with Canavan disease, a neurodegenerative disorder that begins at birth. Individuals with Canavan disease lack the enzyme aspartoacylase, which is produced by the ASPA gene.
↧